Intervention: Real-life use of CAR-T cell therapy (autologous, genetically engineered T-cell immunotherapy). Mechanism: Patient T cells are transduced to express a chimeric antigen receptor that binds tumor surface antigens independent of HLA, CAR signaling (CD3ζ with CD28 or 4‑1BB co-stimulatory domains) activates T-cell proliferation, cytokine release, and cytolytic killing of tumor cells. Targets: Primarily B-lineage malignancies via anti‑CD19 CAR-T and plasma-cell malignancies via anti‑BCMA CAR-T, targeted cells include malignant B cells and plasma cells. Pathways engaged: CAR-mediated immune synapse formation, T-cell activation cascades, apoptosis of target cells, and broader immune effector/cytokine pathways. Study type: Ambispective observational cohort assessing care pathways, access, and quality of life for patients eligible for CAR‑T at Toulouse University Hospital.